WO2024172778 - NOVEL POLYMORPH OF RUXOLITINIB HEMIFUMARATE AND METHOD OF PREPARATION
National phase entry is expected:
Publication Number
WO/2024/172778
Publication Date
22.08.2024
International Application No.
PCT/TR2023/050151
International Filing Date
16.02.2023
Title **
[English]
NOVEL POLYMORPH OF RUXOLITINIB HEMIFUMARATE AND METHOD OF PREPARATION
[French]
NOUVEAU POLYMORPHE D'HÉMIFUMARATE DE RUXOLITINIB ET PROCÉDÉ DE PRÉPARATION
Applicants **
DEVA HOLDING
Inventors
HAAS, Philipp Daniel
STECKEL, Hartwig Andreas
BELLUR ATİCİ, Esen
BOSTANCIOĞLU, Gamze
SOYER CAN, Okşan
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
Turkpatent
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1899 | |
| EPO | Filing, Examination, Granting | 8950 | |
| Japan | Filing, Examination, Granting | 2130 | |
| South Korea | Filing, Examination, Granting | 1782 | |
| USA | Filing, Examination, Granting | 5940 |
Total:
20,701
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to a new crystalline polymorphic form of ruxolitinib hemifumarate, namely Form III, and methods for its preparation. The new crystalline polymorph Form III of ruxolitinib hemifumarate is characterized by an XRPD pattern having characteristic peaks (2-theta ± 0.2º) at 13.7, 19.3, 21.5 and 22.7. The present invention also provides pharmaceutical compositions comprising Form III of ruxolitinib hemifumarate, and medical use of Form III.[French]
La présente invention concerne une nouvelle forme polymorphe cristalline d'hémifumarate de ruxolitinib, à savoir la forme III, et des procédés pour sa préparation. La nouvelle forme polymorphe cristalline III d'hémifumarate de ruxolitinib est caractérisée par un diagramme XRPD ayant des pics caractéristiques (2-thêta ± 0,2°) à 13,7,19,3, 21,5 et 22,7. La présente invention concerne également des compositions pharmaceutiques comprenant la forme III d'hémifumarate de ruxolitinib, et l'utilisation médicale de la forme III.